---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-303190"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-07-14T20:15:12+00:00"
generated_at: "2026-07-14T20:16:16.051584+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health subsidiary Napo enters new 3-year manufacturing agreement with Alivus for crofelemer supply

## Summary
- New agreement with Alivus Life Sciences for manufacture of crofelemer for Mytesi and other products.
- Term from July 9, 2026 to March 31, 2029; replaces prior agreement that expired March 31, 2026.
- Includes minimum purchase quantities; shortfall payment obligation if not met.
- May be terminated for any reason with 12 months' notice, or for material breach with 90-day cure.
- In insolvency, rights assigned to Woodward Specialty LLC (affiliate of Future Pak).

## SEC filing metadata
- accession: 0001193125-26-303190
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-07-14T20:15:12+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526303190/0001193125-26-303190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526303190/d144017d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-303190
- JSON: https://secwatch.observer/filing/0001193125-26-303190.json
- Plain text: https://secwatch.observer/filing/0001193125-26-303190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.